1. Infection

Infection

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W250308A
    ε-Poly-L-lysine hydrochloride (MV 2000-5000) 99%
    ε-Poly-L-lysine (Epsilon-polylysine; ε-Polylysine) hydrochloride (MV 2000-5000) is a polycationic antibacterial agent with broad-spectrum activity against Gram-positive bacteria, Gram-negative bacteria, fungi, yeasts and specific bacteriophages. ε-Poly-L-lysine hydrochloride (MV 2000-5000) exerts bactericidal effects through mechanisms such as disrupting microbial membranes, inducing ROS production, inhibiting metabolism and spore germination. ε-Poly-L-lysine hydrochloride (MV 2000-5000) also regulates the expression of multiple key genes including sodA, oxyR and recA. ε-Poly-L-lysine hydrochloride (MV 2000-5000) exhibits properties such as low eukaryotic cytotoxicity, thermal stability and pH stability, and supports tissue regeneration and anti-tumor applications. ε-Poly-L-lysine hydrochloride (MV 2000-5000) can be applied in research fields including bacterial and fungal infections, diabetic ulcers, and methicillin-resistant Staphylococcus aureus infections.
    ε-Poly-L-lysine hydrochloride (MV 2000-5000)
  • HY-50898B
    Lapatinib ditosylate monohydrate 388082-78-8 99.99%
    Lapatinib ditosylate monohydrate (GW572016 ditosylate monohydrate) is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively.
    Lapatinib ditosylate monohydrate
  • HY-103714A
    Ensartinib dihydrochloride 2137030-98-7 99.73%
    Ensartinib dihydrochloride (X-396 dihydrochloride) is a BBB-permeable and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively.
    Ensartinib dihydrochloride
  • HY-10045
    AEE788 497839-62-0 98.39%
    AEE788 is an orally active inhibitor targeting EGFR and ErbB2 with IC50 values of 2 and 6 nM, respectively[1][2][3].
    AEE788
  • HY-B1907
    Rifamycin sodium 14897-39-3 99.56%
    Rifamycin sodium (Rifamycin SV monosodium) is an orally active ansamycin antibiotic. Rifamycin sodium inhibits DNA-dependent RNA synthesis. Rifamycin sodium has antibacterial activity against Mycobacterium tuberculosis. Rifamycin sodium interferes with hepatic bile acid metabolism. Rifamycin sodium has anti-inflammatory effects. Rifamycin sodium can be used in the study of Mycobacterium tuberculosis, Bacteroides fragilis infection, and Lipopolysaccharide (HY-D1056B3)-induced inflammation.
    Rifamycin sodium
  • HY-107813
    Amikacin sulfate 149022-22-0 99.91%
    Amikacin sulfate (BAY 41-6551 sulfate) is an aminoglycoside antibiotic and a semisynthetic analog of kanamycin. Amikacin sulfate is bactericidal, acting directly on the 30S and 50S bacerial ribosomal subunits to inhibit protein synthesis. Amikacin sulfate is very active against most Gram-negative bacteria including gentamicin- and tobramycin-resistant strains. Amikacin sulfate also inhibits the infections caused by susceptible Nocardia and nontuberculous mycobacteria.
    Amikacin sulfate
  • HY-15728
    Radotinib 926037-48-1 99.19%
    Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC50 of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases.
    Radotinib
  • HY-141882
    DC-LC3in-D5 2868312-73-4 98.62%
    DC-LC3in-D5 acts as an autophagy inhibitor by attenuating LC3B lipidation. DC-LC3in-D5 binds with LC3B. DC-LC3in-D5 disrupts the LC3B-LBP2 interaction with an IC50 of 200 nM. DC-LC3in-D5 may contribute to anti-HCV or combination researchs in cancer through inhibiting autophagy.
    DC-LC3in-D5
  • HY-148560
    ccc_R08 2919019-72-8 98.87%
    ccc_R08 is a non-cytotoxic and orally active cccDNA inhibitor that reduces cccDNA levels in the liver of HBV-infected mice. ccc_R08 can be used in the study of HBV virus (hepatitis B virus) infection.
    ccc_R08
  • HY-P99804
    Clesrovimab 2429913-18-6 99.77%
    Clesrovimab (MK1654) is a humanized IgG1 monoclonal antibody targeting the respiratory syncytial virus (RSV) protein F. Clesrovimab binds to pre-fusion and post-fusion forms of RSV-A fusion protein with high affinity, with corresponding KD values of 71 pM and 480 pM, respectively. Clesrovimab is applicable for the research of RSV infection.
    Clesrovimab
  • HY-15664
    Bivalirudin TFA 1191386-55-6 99.95%
    Bivalirudin TFA, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin TFA inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin TFA also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin TFA can be used for the research of thrombotic diseases and others.
    Bivalirudin TFA
  • HY-16911
    AFN-1252 620175-39-5 99.49%
    AFN-1252 is an orally active and selective inhibitor of FabI, an essential enzyme in fatty acid biosynthesis in Staphylococcus spp. AFN-1252 exhibits exquisite and highly selective activity against Staphylococcus spp. AFN-1252 exhibits typical MIC90 values of ⩽0.015 μg/ml against diverse clinical isolates of S. aureus. AFN-1252 is efficacious in a mouse model of septicemia providing 100% protection from an otherwise lethal peritoneal infection of S. aureus Smith.
    AFN-1252
  • HY-17396
    Butenafine Hydrochloride 101827-46-7 99.95%
    Butenafine Hydrochloride (KP363 Hydrochloride) is a synthetic benzylamine antifungal, works by inhibiting the synthesis of sterols by inhibiting squalene epoxidase.
    Butenafine Hydrochloride
  • HY-B0027
    Valnemulin hydrochloride 133868-46-9 98.13%
    Valnemulin hydrochloride is an orally effective truncated pleurotin antibiotic that inhibits protein synthesis in bacteria by binding to peptidyl transferase in the 50s ribosome subunit. Valnemulin hydrochloride effectively eliminates Mycobacterium bovis in the lungs in an experimental bovine model of Mycoplasma bovis infection. Valnemulin hydrochloride can reduce the mortality of epidemic rabbit enteropathy and has no adverse effect on the growth performance of rabbits.
    Valnemulin hydrochloride
  • HY-B0935
    Benzyl benzoate 120-51-4 99.98%
    Benzyl benzoate (Phenylmethyl benzoate) is an orally active anti-scabies agent, acaricide (EC50= 0.06 g/m2) and fungicide. Benzyl benzoate is an angiotensin II (Ang II) inhibitor with antihypertensive effects. Benzyl benzoate can be used in perfumes, pharmaceuticals and the food industry.
    Benzyl benzoate
  • HY-B1400
    Diiodohydroxyquinoline 83-73-8
    Diiodohydroxyquinoline (Iodoquinol, 5,7-Diiodo-8-hydroxyquinoline, 5,7-Diiodo-8-quinolinol) has an orally active and satisfactory antiparasitic properties. Diiodohydroxyquinoline exhibits mutagenic potential in mice and potent anti-SARS-CoV-2 activity with an EC50 value of 1.38 μM in VeroE6 cells. Diiodohydroxyquinoline's antimutagen is ascorbic acid. Diiodohydroxyquinoline is promising for research in inflammationin, testinal amebiasis, amebic liver abscess and chronic nonspecific diarrheas.
    Diiodohydroxyquinoline
  • HY-B1415
    Clofibric acid 882-09-7 99.92%
    Clofibric acid (Chlorofibrinic acid) is an orally active PPARα agonist. Clofibric acid inhibits the fimbriation of Escherichia coli. Clofibric acid increases SOD activity. Clofibric acid lowers blood lipids and prevents experimental pyelonephritis. Clofibric acid has anticancer activity against ovarian cancer. Clofibric acid is also a herbicide. Clofibric acid is used in ovarian cancer, liver cancer, obesity, and urinary tract infection research.
    Clofibric acid
  • HY-B1790
    Terconazole 67915-31-5 99.93%
    Terconazole is a broad-spectrum antifungal medication for the treatment of vaginal yeast infection.
    Terconazole
  • HY-B1805
    Triclocarban 101-20-2 98.93%
    Triclocarban (3,4,4′-Trichlorocarbanilide), a broad spectrum antibacterial compound, is widely used in a broad range of applications such as the production of soaps, skin creams, toothpastes and deodorants. Triclocarban is a potential endocrine-disrupting chemical with the capacity to modulate androgen and estrogen activities as well as other hormone-mediated biological processes.
    Triclocarban
  • HY-N0941
    beta-Mangostin 20931-37-7 99.84%
    beta-Mangostin (β-Mangostin) is a xanthone compound present in Cratoxylum arborescens, with antibacterial and antimalarial activities. beta-Mangostin exhibits antimycobacterial activity against Mycobacterium tuberculosis with an MIC of 6.25 μg/mL. beta-Mangostin possesses in vitro antimalarial activity against Plasmodium falciparum, with an IC50 of 3.00 μg/mL. beta-Mangostin has potent anticancer activity against various cancers (such as hepatocellular carcinoma, leukaemic).
    beta-Mangostin
Cat. No. Product Name / Synonyms Application Reactivity